Ascendis Pharma Stock Forecast

Stock Price Forecast

According to 18 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $308.72. The average 1-year stock price forecast is 26.57% higher than the current stock price, while the lowest is $260.36 (+6.74%) and the highest is $357.77 (+46.68%).

Price Target: $308.72 (+26.57%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$260.36	$308.72	$306.83	$357.77
Change	+6.74%	+26.57%	+25.80%	+46.68%

Analyst Ratings

The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	3	13	14	14
Buy	1	4	4	4
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	4	17	18	18

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Paul Choi Goldman Sachs	Goldman Sachs	Buy Maintains $260 → $300	Buy	Maintains	$260 → $300	+23.00%	Jul 27, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Buy Maintains $256 → $275	Buy	Maintains	$256 → $275	+12.75%	Jul 23, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Buy Reiterates $288 → $306	Buy	Reiterates	$288 → $306	+25.46%	Jul 14, 2026
Yun Zhong Wedbush	Wedbush	Buy Reiterates $273 → $327	Buy	Reiterates	$273 → $327	+34.07%	Jul 9, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $345	Buy	Maintains	$345	+41.45%	Jul 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.34B

from 720.13M

86.49%

from 720.13M

Revenue Next Year

1.97B

from 1.34B

46.46%

from 1.34B

EPS This Year

11.73

from -

EPS Next Year

9.29

from 11.73

-20.85%

from 11.73

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Jan 1, 2023	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	7.78M	51.17M	266.72M	363.64M	720.13M	1.34B
Revenue Growth	11.87%	557.93%	421.20%	36.34%	98.03%	86.49%
Gross Profit	4.26M	39.04M	222.32M	319.38M	625.22M	1.20B
Gross Margin	54.71%	76.28%	83.36%	87.83%	86.82%	89.48%
Operating Income	-451.79M	-561.81M	-455.54M	-278.76M	-136.27M	327.43M
Net Income	-383.58M	-583.19M	-481.45M	-378.08M	-228.03M	911.25M
EPS	-	-	-	-	-	11.73
Forward PE	-	-	-	-	-	18.02
Free Cash Flow	-281.90M	-156.42M	-332.95M	-200.32M	164.71M	409.65M
No. Analysts	-	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.5B
Avg	1.3B
Low	1.3B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	104.7%
Avg	86.5%
Low	77.5%

EPS Forecast

Chart

EPS	2026	2027	2028
High	16.83
Avg	11.73
Low	4.11

EPS Growth

Chart

EPS Growth	2027	2028
High	-10.5%
Avg	-20.8%
Low	-32.7%